Physician profile
Roopa Gupta
NPI 1194944496
$7,987.60
in general payments reported to CMS, 2019-2025
69 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $211 · 2021: $251 · 2022: $2,065 · 2023: $343 · 2024: $1,810 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,023 · Education: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,023.29 |
| Education | $570.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,238.82 | 2019-2025 | Enhertu, Injectafer |
| Pfizer INC. | $375.05 | 2019-2025 | |
| Janssen Biotech, INC. | $354.33 | 2019-2025 | Rybrevant, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $302.43 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Amgen INC. | $273.41 | 2019-2024 | Kyprolis, Blincyto |
| Seagen INC. | $234.41 | 2020-2025 | Tukysa |
| Glaxosmithkline, LLC. | $217.11 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $217.03 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $179.71 | 2019-2025 | Opdivo |
| Astellas Pharma US INC | $166.90 | 2020-2025 | Vyloy, Padcev |
| Genentech USA, INC. | $159.08 | 2019-2025 | Itovebi, Tecentriq, Phesgo |
| Emd Serono, INC. | $136.08 | 2019-2025 | |
| Stemline Therapeutics INC. | $129.51 | 2024-2025 | Orserdu |
| Incyte Corporation | $126.30 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Asd Specialty Healthcare, LLC | $124.21 | 2023-2024 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.